ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
A phase 3 trial of Limertinib run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active.
Overview
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT04143607 by Jiangsu Aosaikang Pharmaceutical Co., Ltd., with 337 participants enrolled, started 2019-07-23. Conditions listed: Locally Advanced or Metastatic NSCLC. No results are recorded here; the registry entry is the source.
Setting
A Phase III,Double-Blind, Randomised Study to Assess the Efficacy and Safety of ASK120067 Versus Gefitinib as First-Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase
Phase 3
Sponsor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Registry
Enrolled
337